Current Trials

p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.

When we say someone has p53 wildtype cancer, it means their guardian (p53) is working as it should. It’s like having a strong and reliable guardian who can keep an eye on things and prevent trouble (like stopping cells from growing out of control).

So, in simple terms, p53 wildtype cancer means the guardian in the body is doing its job properly, but still, cancer has somehow developed.

The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wildtype endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomised in a 1:1 ratio to maintenance therapy with either Selinexor or placebo.

The target population for this study are Mayo Stage IV AL amyloid patients

This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients

Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia

ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.

Cancer Associated Venous Thromboembolism

The purpose of this study is to compare the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE.

High-risk early triple negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene. For this study high-risk early TNBC is defined as any presence of TNBC that still remains in the breast or lymph node tissue after receiving treatment and undergoing surgery.

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in patients with high-risk early TNBC when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.

Blood Cancer

Healthy Volunteers for Research and Development Purpose

Clinical Haematology Patients

Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Non-Small Cell Lung Cancer

The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC

Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

Relapsed or refractory multiple myeloma

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

No new patients will be recruited to this study. The original study involved patients with breast cancer treated with Trastuzumab.If you participated in the CTRIAL-IE (ICORG) 08-01 CADY study on cardiac dysfunction in HER-2 positive breast cancer patients, please read this important data protection notice. Cancer Trials Ireland, in collaboration with Abbott Laboratories, is conducting a follow-up sub-study to re-test stored biological samples using advanced biomarker technology and review medical records for cardiovascular outcomes. This research aims to improve early detection of heart risks in breast cancer patients treated with Trastuzumab. Your data remains securely stored and protected, with strict access controls. If you wish to learn more, withdraw consent, or exercise your data rights, click here to read the full notice.

The study aims to:
(1) Evaluate the predictive capability of chosen cardiac biomarkers in forecasting cardiac dysfunction in breast cancer patients treated with Trastuzumab.
(2) Develop a predictive model using machine learning techniques based on the most accurate and sensitive combination of biomarkers.

ER+/HER2- early breast cancer with intermediate-high or high risk of recurrence

The purpose of this study is to measure the safety and demonstrate the superiority of camizestrant +/- abemaciclib as compared to standard endocrine therapy +/- abemaciclib by assessment of invasive breast cancer-free survival

Patients with histologically proven adenocarcinoma of the GEJ type II

The objective of this study is to compare transthoracic esophagectomy versus transhiatal extended gastrectomy inpatients in patients with adenocarcinoma of the gastroesophageal junction (GEJ) type II